Weight-loss injections: How do drugs like Wegovy and Mounjaro work?
BBC World
February 24, 2026
AI-Generated Deep Dive Summary
Weight-loss injections like Wegovy and Mounjaro are gaining popularity in the UK, with around 1.6 million people currently using them. While some patients can access these medications through the NHS, most opt to purchase them privately due to limited availability on the public healthcare system. These injectable drugs work by mimicking GLP-1, a hormone that reduces appetite and promotes feelings of fullness, helping users lose weight effectively. However, experts caution that stopping the medication often leads to regain, emphasizing the importance of combining these treatments with healthy eating and exercise.
Wegovy and Mounjaro are available in different forms: semaglutide (Wegovy) as a weekly injection pen and tirzepatide (Mounjaro) for managing metabolism and energy balance. Clinical trials have shown significant weight loss, with Mounjaro users losing 20% of their body weight compared to Wegovy's 14%. The NHS recommends these drugs for individuals with obesity-related health conditions, such as high blood pressure or diabetes, rather than those seeking minor weight loss. Prescriptions are typically limited to two years and come with strict eligibility criteria based on BMI and medical history.
Private purchases of these injections are widespread, with costs ranging from £100 to £300 per pen. However, patients must ensure they obtain the medication from regulated sources to avoid complications. Side effects include nausea, vomiting, bloating, constipation, and hair loss, though many users find these manageable. Rare but serious side effects like gallbladder or kidney issues have been reported, highlighting the need for proper medical supervision.
The availability of these drugs reflects a broader trend in global healthcare, where innovative treatments are being leveraged to address obesity and related health risks. The demand underscores the growing recognition of obesity as a critical public health issue, prompting governments and healthcare providers to adapt their approaches to weight management. For readers interested in world affairs and policy, this development highlights the intersection of medical innovation and public health strategy, offering insights into how governments balance accessibility with resource constraints.
Ultimately, while Wegovy and Mounjaro represent significant advancements in weight-loss treatment, they are
Verticals
worldpolitics
Originally published on BBC World on 2/24/2026